JUN 14, 2018 03:10 PM PDT

The Rise of Carbapenem Resistance

WRITTEN BY: Carmen Leitch

European scientists are warning about the rise of a dangerous group of microbes that resist the effects of an important class of drugs called carbapenems. These drugs, which include doripenem, ertapenem, imipenem, and meropenem, work against many different kinds of pathogenic microbes and are used when other drugs fail. However, bacteria are becoming resistant to them; such pathogens are now thought to pose a significant threat to the patients in the healthcare clinics of every country in the European Union. A Rapid Risk Assessment about these conclusions has been released by the European Centre for Disease Prevention and Control. 

First reported in the nineties, resistance to carbapenems has since become more common and spread to more areas of the globe. It’s one type of bacteria, Enterobacteriaceae, that is gaining the upper hand on the drugs, as they become carbapenem-resistant Enterobactericaeae, or simply CRE. CRE infections pose a real danger.

"We should be very concerned about the rise in carbapenem resistance in the EU/EEA as there are very few options for the treatment of patients with CRE infections,” said Dominique Monnet, the Head of ECDC's Antimicrobial Resistance and Healthcare-Associated Infections Programme. "In recent years, the proportions of carbapenem resistance in Klebsiella pneumoniae - a type of Enterobacteriaceae - rapidly increased to high levels in Greece, Italy, and Romania. The same could happen to other EU/EEA countries if appropriate measures are not taken. But the spread of CRE can likely be controlled in most countries through the implementation of appropriate prevention and control measures in hospitals and other healthcare settings."

CRE infections of the bloodstream and urinary tract are not unusual in hospitals, and they can make a patient's stay in the hospital longer and increase the cost of treating patients. They can also contribute to failures in treatment and cause death; treating these infections is challenging, and there are limited options, especially for patients in hospitals.
While the prevalence of these infections is still low, in Europe the national percentages of bloodstream infections caused by Klebsiella pneumonia that is carbapenem-resistant ranges from zero to 67 percent. The highest rates are in Romania, Italy, and Greece; those countries have rates of 31, 34 and 67 percent, respectively.

When antibiotic resistance becomes a frequent occurrence, that antibiotic ceases to be recommended for use. There aren’t any antibiotics that are a good choice for fighting a CRE infection. 

Global travel and patient transfer can introduce CRE into new countries or countries where the prevalence is low. Some places, like Southeast Asia and India, have high levels of CRE.

Enterobacteriaceae / Credit: Pixnio

It will be important for clinics to monitor for these infections carefully, and to mount an effective response when they occur. The ECDC's Rapid Risk Assessment highlights steps doctors can take.


Sources: AAAS/Eurekalert! via ECDC, Merck Manuals

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 02, 2018
AUG 02, 2018
Chronic Infections Outsmart the Immune System
Chronic parasitic infection shown to take advantage of a mechanism to sustain infection and induce death of white blood cells essential to immune response....
AUG 14, 2018
AUG 14, 2018
How Ebola Gets Into Cells
Researchers have learned how Ebola gains entry to cells, which can help us stop it....
SEP 05, 2018
Earth & The Environment
SEP 05, 2018
Climate change increases prevalence of parasites among livestock
A warming climate will ultimately favor some species over others. One such species is a parasite called the liver fluke, which infects livestock with a dis...
SEP 11, 2018
Drug Discovery
SEP 11, 2018
Potential Non-Antibiotic Drug For Tuberculosis
After 10 years of research, scientists at the University of Manchester have created the first non-antibiotic drug that can successfully treat tuberculosis ...
SEP 29, 2018
SEP 29, 2018
How Researchers Study the Microbes in the Human Gut
Researchers are starting to learn a lot more about the huge number of microbes living in our gastrointestinal tract. But how?...
OCT 22, 2018
OCT 22, 2018
How Many Bacteria are There in the World?
Researchers once thought that there were only a few thousand bacterial species on the planet - a gross underestimation....
Loading Comments...